trending Market Intelligence /marketintelligence/en/news-insights/trending/5u_2nzbzAvo611ITF4LI-A2 content esgSubNav
In This List

Paris court rules against Onxeo in SpePharm, SpeBio dispute

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Paris court rules against Onxeo in SpePharm, SpeBio dispute

The Commercial Court of Paris ruled against Onxeo SA in its dispute with SpePharm and their 50-50 joint venture SpeBio BV.

SpeBio BV was formed to distribute Loramyc for the treatment of oropharyngeal candidiasis, a yeast/fungal infection.

The court directed Onxeo to pay SpePharm and SpeBio €50,000 and €8.6 million in damages, respectively. SpePharm and SpeBio will also receive procedural indemnities of €15,000 and €250,000, respectively.

Onxeo said it will contest the decision.

The dispute, which Onxeo started in 2009, involves alleged contract breaches by SpePharm and SpeBio that resulted in a delay in the marketing and sales of Loramyc.

Onxeo was formerly known as BioAlliance Pharma.